Skip to main content
S. 3131 118th Congress Senate

ORPHAN Cures Act

Official title: A bill to amend title XI of the Social Security Act to expand and clarify the exclusion for orphan drugs under the Drug Price Negotiation Program.

Introduced: October 25, 2023 Introduced by: John Barrasso Republican · Wyoming See on congress.gov
Health Health care costs and insuranceMedicarePrescription drugs
Sign in to write a letter Sign in to watch
This bill died when the 118th Congress ended
It never became law before the 118th Congress (2023–2024) adjourned, and bills don't carry over to the next Congress. It would have to be reintroduced. You can still save it for reference, but it won't receive updates.
 Everywhere this bill has been 2 steps
Introduced
In committee
Reported out
Passed House
Passed Senate
To President
Became law
Oct 25, 2023
Read twice and referred to the Committee on Finance.
Oct 25, 2023
Introduced in Senate
 Ask about this bill AI · grounded in the bill text

Have a question about what this bill does? Ask in plain English; the answer is drawn from the bill's actual text and official record, and it'll tell you when something isn't in the text rather than guess.

AI answers can be imperfect; always confirm against the full bill text.

 Latest action October 25, 2023

Read twice and referred to the Committee on Finance.

 Related & companion bills 1
 Bill text 1 version

Source documents hosted by congress.gov.

 Committees of jurisdiction 1
 Lobbying activity 9

Registered lobbyists who named this bill in their disclosure filings. Source: federal Lobbying Disclosure Act filings.

  • BRIDGEBIO PHARMA, INC.
    for BRIDGEBIO PHARMA, INC. · California · 4th Quarter 2023 (Oct 1 - Dec 31)
  • TODD STRATEGY GROUP
    for NOVARTIS, INC. · District of Columbia · 2nd Quarter 2026 (Apr 1 - June 30)
  • TODD STRATEGY GROUP
    for NOVARTIS, INC. · District of Columbia · 1st Quarter 2026 (Jan 1 - Mar 31)
  • TODD STRATEGY GROUP
    for NOVARTIS, INC. · District of Columbia · 4th Quarter 2025 (Oct 1 - Dec 31)
  • TODD STRATEGY GROUP
    for NOVARTIS, INC. · District of Columbia · 3rd Quarter 2025 (July 1 - Sep 30)
  • TODD STRATEGY GROUP
    for NOVARTIS, INC. · District of Columbia · 2nd Quarter 2025 (Apr 1 - June 30)

Bodies those filers lobbied

A filing lists the bills it worked on and the parts of government it contacted in separate sections, so these are the bodies those filers named anywhere in the filing, not a per-bill breakdown.

See all 9 filings →
 Cosponsors 2
All 2 Republican 2
R
Budd, Ted
North Carolina · Jul 9, 2024
 R
Marshall, Roger
Kansas · Jul 9, 2024
Cite this page click to expand
APA
U.S. Congress. (2026). S. 3131: ORPHAN Cures Act. 118th Congress. Open America. https://openamerica.io/bill/118-S-3131/
MLA
"S. 3131: ORPHAN Cures Act." 118th Congress, 2026, Open America, https://openamerica.io/bill/118-S-3131/.
Bluebook (legal)
S. 3131, 118th Cong. (2026), https://openamerica.io/bill/118-S-3131/.
Markdown link
[S. 3131: ORPHAN Cures Act](https://openamerica.io/bill/118-S-3131/)
Report a problem